Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner.

Abstract	Dysregulation of the Hippo pathway occurs in a variety of cancers and often correlates with a poor prognosis. To further explore the potential role of Hippo pathway dysregulation in tumor development and progression, we investigated its downstream transcription factor TEAD4 in colorectal cancer (CRC). Increased expression and nuclear localization of TEAD4 were found in a significant portion of CRC tissues, in association with metastasis and a poor prognosis. In CRC cells, TEAD4 knockdown induced the mesenchymal-epithelial transition and decreased cell mobility in vitro and metastasis in vivo. Microarray analysis revealed that TEAD4 promoted cell adhesion and upregulated the epithelial-mesenchymal transition-related transcriptome in CRC cells. Vimentin was identified as a new direct target gene mediating TEAD4 function in CRC cells, whereby forced vimentin expression markedly reversed TEAD4-knockdown-induced cell morphological changes and decreased mobility. Interestingly, rescued expression of both WT TEAD4 and a Y429H mutant can reverse the mesenchymal-epithelial transition and increase vimentin expression, cell mobility and metastatic potential in TEAD4-knockdown CRC cells. The discrepant expression of YAP and TEAD4 in CRC tissues, the rescue ability of TEAD4 mutant defect in YAP binding and no effect on vimentin expression by YAP knockdown in CRC cells, all implicated a YAP-independent manner of TEAD4 function in CRC. Furthermore, vimentin positively correlated and CDH1 reversely correlated with the level of TEAD4 in CRC tissues and xenograft tumors. Our results suggest that TEAD4 nuclear expression can serve as a biomarker for CRC progression and poor prognosis. The transcription factor TEAD4 regulates a pro-metastasis transcription program in a YAP-independent manner in CRC, thus providing a novel mechanism of TEAD4 transcriptional regulation and its oncogenic role in CRC, independently of the Hippo pathway.
Authors	Y Liu, G Wang, Y Yang, Z Mei, Z Liang, A Cui, T Wu, C-Y Liu, L Cui
Journal	Oncogene (Oncogene) Vol. 35 Issue 21 Pg. 2789-800 (05 2016) ISSN: 1476-5594 [Electronic] England
PMID	26387538 (Publication Type: Journal Article)
Chemical References	Adaptor Proteins, Signal Transducing DNA-Binding Proteins Muscle Proteins Phosphoproteins TEA Domain Transcription Factors TEAD4 protein, human Transcription Factors YAP-Signaling Proteins YAP1 protein, human Protein Serine-Threonine Kinases
Topics	Adaptor Proteins, Signal Transducing (metabolism) Animals Apoptosis (physiology) Cell Line, Tumor Cell Nucleus (metabolism) Cell Proliferation (physiology) Colorectal Neoplasms (metabolism, pathology) DNA-Binding Proteins (biosynthesis, metabolism) Epithelial-Mesenchymal Transition Heterografts Hippo Signaling Pathway Humans Male Mice Mice, Nude Muscle Proteins (biosynthesis, metabolism) Neoplasm Metastasis Phosphoproteins (metabolism) Prognosis Protein Serine-Threonine Kinases (metabolism) TEA Domain Transcription Factors Transcription Factors (biosynthesis, metabolism) Transcriptional Activation Transfection YAP-Signaling Proteins

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!